TRIM2 suppresses prostate cancer progression by promoting ubiquitin-mediated degradation of DTNBP1
The findings establish the TRIM2-DTNBP1 axis as a key driver of PCa progression and position TRIM2 as a promising prognostic biomarker and a potential predictive indicator for guiding molecularly targeted therapies in advanced PCa.